{"id":"pazopanib-or-guideline-conform-chemotherapy","safety":{"commonSideEffects":[{"rate":"31","effect":"Diarrhea"},{"rate":"40","effect":"Hypertension"},{"rate":"38","effect":"Hair color changes"},{"rate":"26","effect":"Nausea"},{"rate":"22","effect":"Anorexia"},{"rate":"13","effect":"Vomiting"},{"rate":"19","effect":"Fatigue"},{"rate":"53","effect":"Hepatotoxicity (elevated transaminases)"},{"rate":"12","effect":"Thrombocytopenia"},{"rate":"3","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pazopanib inhibits multiple receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α and -β), and c-Kit. By blocking these pathways, it reduces tumor blood vessel formation (angiogenesis) and directly inhibits cancer cell growth and survival. The guideline-conform chemotherapy component refers to standard cytotoxic chemotherapy regimens used as comparative or alternative treatment options.","oneSentence":"Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:59.954Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced renal cell carcinoma"},{"name":"Advanced soft tissue sarcoma"},{"name":"Ovarian cancer (in combination with chemotherapy)"}]},"trialDetails":[{"nctId":"NCT03735758","phase":"PHASE4","title":"Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib","status":"TERMINATED","sponsor":"GWT-TUD GmbH","startDate":"2018-11-02","conditions":"Soft Tissue Sarcoma Adult","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"pazopanib or guideline conform chemotherapy","genericName":"pazopanib or guideline conform chemotherapy","companyName":"GWT-TUD GmbH","companyId":"gwt-tud-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pazopanib is a multi-targeted tyrosine kinase inhibitor that blocks angiogenesis and tumor cell proliferation by inhibiting VEGFR, PDGFR, and c-Kit signaling. Used for Advanced renal cell carcinoma, Advanced soft tissue sarcoma, Ovarian cancer (in combination with chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}